BILLERICA, Mass. / Feb 20, 2025 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences:
Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York City
Thursday, February 27, 2025, at 2:30 p.m. Eastern Time
TD Cowen 45th Annual Health Care Conference in Boston, MA
Wednesday, March 5, 2025, at 11:10 a.m. Eastern Time
Barclays 27th Annual Global Healthcare Conference in Miami, FL
Tuesday, March 11, 2025, at 2:30 p.m. Eastern Time
Leerink 2025 Global Healthcare Conference in Miami, FL
Wednesday, March 12, 2025, at 11:20 a.m. Eastern Time
Live audio webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for at least 30 days following the presentations.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
| Last Trade: | US$34.06 |
| Daily Change: | -0.55 -1.59 |
| Daily Volume: | 2,933,899 |
| Market Cap: | US$5.170B |
August 06, 2025 August 04, 2025 July 21, 2025 June 03, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
